CAD-1005 Updated Aug 20
Watch for (1) the start/enrollment of the planned 120-patient pivotal Phase 3 trial in HIT, (2) any outcome of the announced partnering process to out-license or co-develop CAD-1005, and (3) financing news, year-end cash of ~$4M was flagged as insufficient to fund Phase 3, and a July 2026 $3M placement already diluted shareholders by ~33%, so another raise is likely before any 2029 NDA. The stock trades near its 52-week low (~$1.66 vs a $14.64 high), and the only near-term analyst action on record is an HC Wainwright Buy maintain; treat the analyst mean target of $14 as far-dated optionality, not a near-term signal.
- Positive Phase 2 result: >25% absolute reduction in thrombotic events in HIT, presented at ISTH 2026 (8-K/analysis and press-release summaries in local data).
- Regulatory momentum: FDA Fast Track and Orphan Drug designations for HIT, plus completed End-of-Phase 2 meeting with a defined pivotal Phase 3 path, a 120-patient randomized placebo-controlled trial described as the first of its kind in HIT.
- Wall Street is constructive: consensus shows 5 Buy + 2 Strong Buy vs 1 Hold and 0 Sell; the 3-analyst price-target snapshot shows mean $14 / high $17 (implied upside ~683% vs the snapshot's $1.87 reference price), with HC Wainwright maintaining Buy in April 2026.
- No revenue and thin cash: ~$4.0M cash at year-end 2025 with a $3.0M quarterly net loss, and management explicitly flagged that cash may not support planned Phase 3 development.
- Heavy dilution already underway: a July 2026 $3M H.C. Wainwright private placement (960,000 shares plus warrants for up to ~$5.8M more) was assessed as ~33% dilutive at a ~$9M market cap; further raises are likely before any 2029 NDA.
- Binary is far away: the pivotal Phase 3 has not even started, and the NDA submission is projected for 2029, no dated regulatory catalyst (PDUFA/readout) within the next 12 months.